The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.

Clinical Research for the Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03073902

Enrollment

Registered

2017-03-08

Start date

2017-03-25

Completion date

2018-12-10

Last updated

2018-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Brief summary

The detection of tissue PD-L1 immunohistochemistry in Non-small cell lung cancer (NSCLC) has an important role in guiding for the treatment of immune detection point. At the same time,tissue detection is time-consuming and laborious, liquid biopsy can reflect the information of tumor tissue,PD-L1 expression in serum and peripheral blood T cell are expected to be simple, rapid, non-invasive means of detection. The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum..The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum.By using variance analysis of repeated measures design information. Thus exploring the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum,guiding clinical practice of immunotherapy.

Interventions

DIAGNOSTIC_TESTLiquid biopsy

Liquid biopsy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Pathological histology and/or cytology confirmed non-small lung cancer; 2. Voluntarily enrolled to participate in,better compliance, cooperate with experimental observations, and sign informed consent.

Exclusion criteria

1. Vital organs (e.g., heart, liver, kidney) have serious dysfunction; 2. Patients with a history of autoimmune disease; 3. Patients with participating in other clinical trials at the same time; 4. Other cases that researchers believe that patients should not participate in the present trial.

Design outcomes

Primary

Measure	Time frame	Description
The match rate of PD-L1 protein expression in non-small lung cancer tissue and peripheral blood T cell .	up to two years	consistency
The match rate of PD-L1 protein expression in non-small lung cancer tissue and serum.	up to two years	consistency

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026